Genotoxic impurities in pharmaceutical products – regulatory, toxicological and pharmaceutical considerations

  • Regulska K
  • Michalak M
  • Murias M
  • et al.
N/ACitations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

This article provides an overview of the most important aspects around the detecting and reporting of genotoxic impurities in the pharmaceutical industry. It focuses on relevant regulatory, toxicological, and pharmaceutical considerations. In this regard, the concept of Threshold of Toxicological Concern is explained and the most common genotoxic impurities are described. Furthermore, toxicological methods for genotoxic impurities screening are presented. Finally, the article emphasises several issues regarding further development.

Cite

CITATION STYLE

APA

Regulska, K., Michalak, M., Murias, M., & Stanisz, B. (2021). Genotoxic impurities in pharmaceutical products – regulatory, toxicological and pharmaceutical considerations. Journal of Medical Science, 90(1), e502. https://doi.org/10.20883/medical.e502

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free